Clinical efficacy and safety: antineoplastic and immunomodulating agents

The European Medicines Agency's scientific guidelines on the clinical evaluation of antineoplastic and immunomodulating agents help medicine developers prepare marketing authorisation applications.

If you have comments on a document which is open for consultation, use the .

Please submit your comments to the following email address:

For a complete list of scientific guidelines currently open for consultation, see Public consultations.


How useful was this page?

Add your rating
1 rating